ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -50.28% | -32.93% | -66.68% | -66.03% | 11.17% |
| Total Depreciation and Amortization | 41.89% | 22.97% | -3.15% | -3.99% | -36.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -27.38% |
| Total Other Non-Cash Items | 99.25% | 53.98% | 140.30% | 203.01% | 17.28% |
| Change in Net Operating Assets | 193.93% | -200.57% | -380.19% | -277.18% | -366.65% |
| Cash from Operations | 56.97% | -37.20% | -123.11% | -80.92% | -47.50% |
| Capital Expenditure | 34.19% | 37.35% | 54.16% | 51.22% | 59.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.00% | -100.00% | 15,622.03% | 15,622.03% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -105.17% | -105.77% | 865.02% | 870.74% | 616.94% |
| Total Debt Issued | -97.03% | -98.45% | 91.26% | 116.85% | 136.16% |
| Total Debt Repaid | 14.53% | 63.18% | -1,178.43% | -1,096.79% | -12,178.13% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.74% | -104.09% | 49.30% | 71.79% | 83.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -196.71% | -196.06% | -84.73% | 763.18% | 512.09% |
